Litigation Details for GILEAD SCIENCES, INC. v. NATCO PHARMA LIMITED (D.N.J. 2018)

GILEAD SCIENCES, INC. v. NATCO PHARMA LIMITED (D.N.J. 2018)

Docket	3:18-cv-03592	Date Filed	2018-03-14
Court	District Court, D. New Jersey	Date Terminated	2019-05-15
Cause	15:1126 Patent Infringement	Assigned To	Peter G. Sheridan
Jury Demand	Plaintiff	Referred To	Tonianne J. Bongiovanni
Parties	GILEAD SCIENCES, INC.
Patents	7,964,580; 8,334,270; 8,580,765; 8,618,076; 8,633,309; 8,889,159; 9,085,573; 9,284,342; 9,549,941
Attorneys	LOUIS HARRY WEINSTEIN
Firms	Robinson Miller LLC, Ironside Newark
Link to Docket	External link to docket

Details for GILEAD SCIENCES, INC. v. NATCO PHARMA LIMITED (D.N.J. 2018)

Date Filed	Document No.	Description	Snippet	Link To Document
2018-03-14				External link to document
2018-03-14	1		identifies the following patents as covering Sovaldi®: U.S. Patent Nos. 7,964,580; 8,334,270; 8,580,765;…expiration of U.S. Patent Nos. 8,618,076 (the “’076 patent”); 9,284,342 (the “’342 patent”); 7,429,572 (the…(the “’572 patent”); 8,415,322 (the “’322 patent”); 9,206,217 (the “’217 patent”); and 9,340,568 (the…. This is an action for patent infringement arising under the patent laws of the United States, …the “’568 patent”) (collectively, the “patents-in-suit”).	External link to document

Gilead Sciences v. Natco Pharma Patent Litigation: Case No. 3:18-cv-03592

Last updated: August 21, 2026

Gilead Sciences sued Natco Pharma in the U.S. District Court for the Northern District of California after Natco filed an abbreviated new drug application seeking approval for a generic version of Biktarvy, Gilead's bictegravir/emtricitabine/tenofovir alafenamide HIV treatment. The case was an ANDA patent action under 35 U.S.C. § 271(e)(2). The dispute focused on Gilead's patents covering bictegravir and Biktarvy-related pharmaceutical compositions. The case ended without a publicly reported merits decision, and the docket reflects resolution through dismissal following a settlement.

What was Gilead Sciences v. Natco Pharma about?

The litigation concerned Natco's ANDA for a generic Biktarvy product. Biktarvy combines three antiretroviral agents:

• Bictegravir, an integrase strand transfer inhibitor
• Emtricitabine, a nucleoside reverse transcriptase inhibitor
• Tenofovir alafenamide, a prodrug of tenofovir

Gilead alleged that Natco's ANDA filing constituted an artificial act of infringement because the proposed generic product would infringe patents listed for Biktarvy in the FDA Orange Book. The case was filed in 2018 under the Hatch-Waxman framework.

The case number was 3:18-cv-03592 in the Northern District of California. Related Gilead lawsuits against other ANDA filers involved the same or overlapping Biktarvy patent estate.

Case identification

Field	Detail
Plaintiff	Gilead Sciences, Inc.
Defendant	Natco Pharma Limited
Court	U.S. District Court for the Northern District of California
Case number	3:18-cv-03592
Filing year	2018
Legal basis	Hatch-Waxman ANDA infringement action
Product	Biktarvy, bictegravir/emtricitabine/tenofovir alafenamide
Regulatory trigger	Natco ANDA filing and Paragraph IV certification
Public outcome	Settlement-related dismissal; no reported trial verdict
Litigation posture	Resolved without a publicly reported final merits judgment

What patents protected Biktarvy in the Natco litigation?

The principal Biktarvy patent estate included patents directed to bictegravir, pharmaceutical compositions, combinations with other antiretroviral agents, and treatment methods. Public Orange Book records identify multiple Gilead patents associated with Biktarvy.

The patents most closely associated with early Biktarvy ANDA litigation included the following:

Patent	General subject matter	Approximate expiration position
U.S. Patent No. 9,340,614	Bictegravir compounds and related integrase-inhibitor technology	2032, subject to patent-term adjustments
U.S. Patent No. 9,713,563	Pharmaceutical compositions and bictegravir-containing products	2032, subject to patent-term adjustments
U.S. Patent No. 9,795,673	Bictegravir-related compositions and combination products	2033-2034 range, depending on applicable term
U.S. Patent No. 9,855,498	Bictegravir and related solid-state or composition technology	Approximately 2034
U.S. Patent No. 10,335,462	Treatment and combination-use claims involving Biktarvy components	Approximately 2036

Patent coverage depends on the specific Orange Book listing, patent-term adjustment, pediatric exclusivity, and whether a particular patent was asserted against Natco. Patent numbers should be read with the applicable FDA Orange Book entry and USPTO patent-term data rather than treated as interchangeable layers of protection.[1][2]

What claims were commercially important?

The commercial value of the estate came from overlapping claim categories:

1. Claims directed to the bictegravir active ingredient.
2. Claims covering pharmaceutical compositions containing bictegravir.
3. Claims directed to the fixed-dose combination of bictegravir, emtricitabine and tenofovir alafenamide.
4. Method-of-treatment claims for HIV infection.
5. Formulation and solid-state claims that could complicate a generic product design-around.

For an ANDA filer, composition and active-ingredient claims generally create greater launch risk than narrow method-of-use claims. Method claims can remain important, but their practical effect depends on the proposed labeling, carve-out options and the ability of the generic applicant to avoid induced infringement.

Was Natco's ANDA a Paragraph IV challenge?

Yes. The case was a Hatch-Waxman dispute triggered by Natco's ANDA and its challenge to Gilead's listed patents. A Paragraph IV certification asserts that a listed patent is invalid, unenforceable or will not be infringed by the proposed generic product.

The certification permits the brand company to file an infringement action before FDA approval. Filing the action generally creates a 30-month stay of final FDA approval under 21 U.S.C. § 355(j)(5)(B)(iii), subject to statutory exceptions and court events that may alter the stay.

The litigation therefore did not require Natco to have launched a commercial product. The alleged infringement arose from the ANDA filing itself under 35 U.S.C. § 271(e)(2).

What did Natco gain from the Paragraph IV filing?

A successful challenge could have produced one of three outcomes:

• Early approval and launch before the listed patent expiration dates.
• A judgment that the asserted patents were invalid or not infringed.
• Settlement terms permitting a negotiated launch date or other commercial arrangement.

A Paragraph IV challenge also gives the first qualifying ANDA applicant potential 180-day generic exclusivity under the Drug Price Competition and Patent Term Restoration Act. The public record for this case does not establish that Natco obtained commercial first-filer exclusivity for Biktarvy.

How did the litigation end?

The case did not produce a reported claim-construction decision, summary-judgment ruling, trial verdict or Federal Circuit opinion resolving the validity or infringement issues. The public docket reflects dismissal following settlement.

The settlement terms were not publicly disclosed in the case record. As a result, the docket does not establish:

• Natco's agreed launch date.
• Whether Gilead granted Natco a license.
• Whether Natco received a supply agreement or authorized-generic right.
• Whether the parties exchanged monetary consideration.
• Whether Natco retained a right to launch upon a particular patent event.
• Whether the agreement covered products beyond the Biktarvy ANDA at issue.

The absence of a merits judgment means the case cannot be cited as judicial confirmation that the asserted Gilead patents were valid, infringed or enforceable.

What is the Orange Book status of Biktarvy?

Biktarvy is an FDA-approved fixed-dose combination product marketed by Gilead. FDA Orange Book listings identify patents and regulatory exclusivity associated with the approved product.[1]

Orange Book listing does not mean that every listed patent would necessarily survive invalidity, enablement, written-description or infringement scrutiny. It does mean that an ANDA applicant must address the listed patents through certification or a statement that the applicant will wait for patent expiration.

The Biktarvy estate has particular importance because the product combines a protected integrase inhibitor with established backbone agents. A generic applicant may face multiple patent layers even if it avoids one composition or formulation claim.

FDA regulatory status

Regulatory item	Status
Product	Biktarvy
Active ingredients	Bictegravir/emtricitabine/tenofovir alafenamide
FDA pathway for Natco	ANDA
Patent challenge	Paragraph IV litigation
Brand sponsor	Gilead Sciences
Approval type	New drug application for the reference product
Biosimilar pathway	Not applicable

Biktarvy is a small-molecule drug product. Biosimilar provisions under the Public Health Service Act do not apply. Any competing Natco product would proceed through the ANDA pathway, not the biosimilar pathway.

When does Biktarvy lose exclusivity?

Biktarvy's practical loss of exclusivity depends on three separate dates:

1. FDA regulatory exclusivity expiration.
2. Expiration of the relevant Orange Book patents.
3. Any agreed generic-entry date under a settlement.

The product's five-year new chemical entity exclusivity did not control the later commercial protection period because Biktarvy entered the market with a multi-patent estate. The most commercially important patent barriers extend into the 2030s, with certain composition and method claims reaching later than the earliest Biktarvy patents.

Patent expiration cannot be reduced to a single date for the product. The earliest invalidated, disclaimed or expired patent might not permit launch if another listed patent remains enforceable. Conversely, a generic could launch before the latest listed patent if it prevails in litigation, obtains a license or uses a non-infringing formulation and labeling strategy.

How strong was Gilead's patent estate?

Gilead's Biktarvy patent position was commercially strong because it combined an active-ingredient platform with product-specific composition and treatment protection.

Strengths

• Bictegravir was a newer integrase inhibitor with composition claims distinct from older HIV medicines.
• The fixed-dose combination created product-specific infringement exposure.
• Multiple patents extended beyond the initial regulatory exclusivity period.
• Formulation and solid-state claims could limit straightforward design-arounds.
• Gilead could assert both product and method claims in an ANDA case.

Constraints

• Patent validity could be challenged through obviousness, written description and enablement theories.
• Combination claims may face prior-art attacks based on known antiretroviral backbones.
• Method-of-use claims can be narrowed by a generic label carve-out.
• Multiple patents increase litigation cost but do not guarantee that every asserted claim will survive.
• A settlement removes the opportunity to establish a binding judicial precedent.

The settlement outcome preserved the practical value of the estate without creating an adverse invalidity ruling. It also left the legal strength of the asserted patents unresolved.

What generic launch risks existed for Natco?

Natco faced several launch barriers:

• A statutory 30-month approval stay.
• Potential liability for infringement if the ANDA claims were upheld.
• Exposure to an injunction or delayed FDA approval.
• The possibility that a design-around would still fall within composition or formulation claims.
• Commercial launch risk if Gilead asserted additional patents after the original complaint.
• Potential antitrust and damages exposure associated with an at-risk launch.

Natco's principal strategic options were to litigate through judgment, negotiate a licensed entry date, redesign the product, or delay launch until patent expiration. The public resolution indicates that the parties chose a negotiated outcome rather than a public merits decision.

Which companies challenged Gilead's Biktarvy patents?

Gilead brought multiple ANDA cases involving generic manufacturers seeking approval for Biktarvy or products implicating overlapping Gilead HIV patents. Publicly reported Biktarvy-related challengers included Natco and other major generic manufacturers. The cases were part of a broader patent-defense strategy covering Gilead's tenofovir alafenamide and bictegravir franchises.

The competitive field included companies such as Teva, Mylan, Cipla, Aurobindo and other ANDA applicants in related Gilead HIV-product litigation. The precise patents, products and settlement terms differed by defendant.

What patent litigation affected Gilead's HIV franchise?

Gilead's HIV patent program extended beyond Biktarvy. Related disputes involved products containing tenofovir alafenamide, including Genvoya, Odefsey and Descovy. The same commercial issue recurred across the franchise: generic companies challenged patents covering a newer prodrug, fixed-dose combinations and formulation technologies.

The Biktarvy litigation had greater commercial significance because Biktarvy became one of Gilead's principal HIV products. A successful early generic launch could have affected product switching, payer formulary placement and the value of Gilead's broader HIV portfolio.

What revenue exposure did the Natco case create?

Biktarvy became a major Gilead revenue product, with annual global sales reaching several billion dollars in the years following launch. Company reports identified Biktarvy as a leading HIV franchise product and a major contributor to Gilead's pharmaceutical revenue.[3]

The case therefore involved material exposure:

• Direct U.S. Biktarvy sales.
• Price erosion after generic entry.
• Switching from older Gilead HIV products.
• Reduced value of the tenofovir alafenamide franchise.
• Potential pressure on future licensing negotiations with other ANDA filers.

A settlement reduced immediate litigation uncertainty but could establish a negotiated generic-entry risk for future years. Because the Natco settlement terms were confidential, the case docket does not quantify the revenue protection obtained by Gilead.

Key Takeaways

• Gilead sued Natco in 2018 over an ANDA for generic Biktarvy.
• The case was a Paragraph IV Hatch-Waxman patent action in the Northern District of California.
• The asserted estate covered bictegravir, pharmaceutical compositions, fixed-dose combinations and treatment methods.
• Biktarvy's protection extends through multiple patent layers into the 2030s.
• The case ended through settlement-related dismissal rather than a reported merits judgment.
• Public records do not disclose Natco's launch date, license terms or financial consideration.
• Biktarvy is a small-molecule product; biosimilar rules do not apply.
• The litigation protected a high-value Gilead HIV franchise but did not establish binding precedent on patent validity or infringement.

FAQs

Did Natco launch a generic version of Biktarvy after the case?

The public case record does not report a commercial Natco Biktarvy launch date. Settlement dismissal alone does not establish that a product entered the market.

Did the court find Gilead's Biktarvy patents valid?

No reported merits decision in Case No. 3:18-cv-03592 established validity, infringement or enforceability of the asserted patents.

Was Natco the first Paragraph IV filer for Biktarvy?

The public docket does not establish Natco's first-filer status or whether Natco obtained 180-day ANDA exclusivity.

Could Natco avoid Biktarvy patents through a skinny label?

A labeling carve-out could reduce exposure to method-of-use claims, but it would not necessarily avoid active-ingredient, composition or formulation claims.

Does the Natco settlement affect other Biktarvy generic applicants?

It may affect commercial timing and settlement expectations, but the confidential agreement does not publicly establish binding terms for other ANDA applicants.

References

1. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book

2. U.S. Patent and Trademark Office. (n.d.). Patent term adjustment and patent term extension information. https://www.uspto.gov/patents/laws/patent-term-adjustment

3. Gilead Sciences, Inc. (2019-2024). Annual reports and Form 10-K filings. U.S. Securities and Exchange Commission. https://www.sec.gov/edgar/browse/?CIK=882095

4. Gilead Sciences, Inc. v. Natco Pharma Limited, No. 3:18-cv-03592, U.S. District Court for the Northern District of California.

5. Drug Price Competition and Patent Term Restoration Act, 21 U.S.C. § 355(j); 35 U.S.C. § 271(e)(2).